Biotricity

Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It is also involved in delivering remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology is comprised of monitoring device and software components, which are made available to the market to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Biotricity achieves positive EBITDA in Q2 2025, poised for growth

Biotricity's Q2 2025 performance showcased positive EBITDA, revenue growth, and operational improvements.
The company's strategic strengths lie in expanding capabilities, forming partnerships, and meeting market demand.
Challenges include sustaining profitability, reducing expenses, and navigating competitive pressures.
Opportunities for Biotricity include growth through partnerships, revenue model optimization, and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. It operates through the following segments: Resting (Non-stress) ECG Systems, Stress ECG Systems, and Holter Monitoring Systems. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.

Follows fiscal third quarter earnings that saw revenue up 93% year-over-year and Company's highest-ever quarterly cash position Biotricity now taking preorders for Biotres, an FDA-cleared, wireless, wearable cardiac arrhythmia monitoring device REDWOOD CITY, CA / ACCESSWIRE / March 4, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it will attend the 34th Annual Roth Conference, being held on March 13-15, 2022 at The Ritz Carlton, Laguna Niguel in Dana Point, California. The conference is one of the largest in the nation for small-cap companies.

Biotricity, Inc. to Attend 34th Annual Roth Conference March 13th-15th

Announcement follows FDA clearance Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022 REDWOOD CITY, CA / ACCESSWIRE / February 23, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company's three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. The Company believes that its wireless, wearable Biotres device offers a secondary product for doctors and hospitals to meet their patients' cardiac monitoring needs and addresses the $5.7 billion cardiac arrhythmia monitoring devices market.

Biotricity Now Taking Pre-Orders for its Biotres Wireless Wearable Cardiac Monitoring Device

Biotricity's (BTCY) CEO Waqaas Al-Siddiq on Q3 2022 Results - Earnings Call Transcript

Management to host investor call on Tuesday February 15th at 4:15 pm ET 93% YOY Revenue Gains to $1.93 Million Revenue Outpaces SG&A Increase by 2.2x Cash Position of $16.8 Million at Quarter End Is Highest Ever Continues to Anticipate Full-Year Triple-Digit Revenue Growth REDWOOD CITY, CA / ACCESSWIRE / February 14, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year's third quarter ended December 31, 2021. Q3-FY22 financial and operating highlights include: Revenue of $1.93 million, an increase of 93% year-over-year and sequentially 7% above the $1.8- million reported in Q2FY22.

Biotricity Releases Fiscal 2022 Third Quarter Financial Results

Management to host call on Tuesday, February 15th at 4:15pm ET Sees Calendar-2022 as a breakout year with commercial launch of Bioheart and FDA clearance for Biotres REDWOOD CITY, CA / ACCESSWIRE / February 8, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, announced that it will release its financial results for the third quarter of fiscal 2022, ended December 31, 2021, on Monday, February 14, 2022, after the close of the market. Additionally, management will host a conference call and live webcast on Tuesday, February 15, 2022 at 4:15 p.m.

Biotricity to Report Third Quarter Fiscal 2022 Financial Results on February 14, 2022

Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2 Billion -dollar holter market REDWOOD CITY, CA / ACCESSWIRE / January 24, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today reported it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients. Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO commented, "We are extremely proud of this accomplishment and its potential to reshape the future of cardiac prevention and monitoring with this novel platform.

Biotricity Receives FDA 510(k) Clearance for its Biotres Cardiac Monitoring Device

New Heart Monitoring Solution Delivers Personalized Heart Health Insights Directly to Your Smartphone Now Easy to Buy and Use: No Prescription Needed for Advanced Heart and Lifestyle Solution REDWOOD CITY, CA / ACCESSWIRE / December 28, 2021 / Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced it has expanded the distribution of its new Bioheart heart monitor system, a direct-to-consumer device that offers the same continuous heart monitoring technology used by physicians, on Amazon.com. Last month the company launched commercial sales of its Bioheart device.

Biotricity Expands Distribution of New Bioheart Device on Amazon.com

Capital infusion to finance inventory and annual recurring revenue subscriptions replaces expiring debt with more favorable terms 5-year term deal strengthens balance sheet, positions company for multiple new product launches in 2022 REDWOOD CITY, CA / ACCESSWIRE / December 27, 2021 / Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced the successful completion of a $12 million non-convertible debt financing. The $12 million capital infusion terms provided by SWK Funding LLC (NASDAQ:SWKH), an investor in healthcare and life science companies, include two years, interest-only period and a 40% principal balloon payment at the end of its five year term.

Biotricity Completes $12 Million Non-Dilutive Debt Financing

The Company believes that it is "well-positioned for 2022." Letter highlights milestones, products roadmap, growth strategy and 2022 goals REDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development.

Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Biotricity Delivers Bioheart: A Groundbreaking Consumer Heart Monitor for Smartphones

Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor

Biotricity's (BTCY) CEO Waqaas Al-Siddiq on Q2 2022 Results - Earnings Call Transcript

Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth Strongest balance sheet since inception REDWOOD CITY, CA / ACCESSWIRE / November 4, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year's second quarter ended September 30, 2021. In its fiscal second quarter, Biotricity reported its tenth consecutive quarter of triple-digit year-over-year revenue growth despite COVID-related headwinds.

Biotricity Releases Fiscal 2022 Second Quarter Financial Results

Management to Host Conference Call and Live Webcast at 5pm ET REDWOOD CITY, CA / ACCESSWIRE / November 2, 2021 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will release its financial results for the second quarter ended September 30, 2021, on Thursday, November 4, 2021, after the close of the market. Additionally, management will host a conference call and live webcast for analysts and investors on November 4, 2021 at 2:00 p.m.

Biotricity to Report Second Quarter Fiscal 2022 Financial Results on November 4, 2021

Progenity

Seelos Therapeutics

Why investors are watching these biotech penny stocks right now The post 3 Biotech Penny Stocks to Watch That Are Climbing Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks to Watch That Are Climbing Right Now

REDWOOD CITY, CA / ACCESSWIRE / October 12, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced that its Chief Executive Officer Waqaas Al Siddiq is scheduled to present in-person at the Virtual LD Micro Main Event XIV in-person on Wednesday, October 13, 2021 at 5:00 PM PT/ 8:00 PM ET. Details are provided below.

Biotricity to Discuss its Breakthrough Patient Monitoring Solutions at Virtual LD Micro Main Event XIV on Oct. 13th

REDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Biotricity Inc. (NASDAQ: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the upcoming release of Biocare Cardiac - a personal, cardiac health application for individuals diagnosed with or at risk for cardiovascular disease. Designed to be used with Samsung's Galaxy Watch4 series, the Biocare Cardiac application continuously collects users' daily activities and provides critical information on their heart performance, empowering patients to better understand and manage their heart conditions.

Biotricity Launches Biocare Cardiac Application for Samsung's Galaxy Watch4 Series

Biotricity Inc (NASDAQ:BTCY) announced the upcoming release of the Biocare Cardiac application to be used with Samsung's Galaxy Watch4 series. Biocare is a personal cardiac health application for individuals diagnosed with or at risk for cardiovascular disease.

Biotricity Launches Cardiac Application For Samsung's Watch4 Series

Founder and CEO Waqaas Al Siddiq and Members of Biotricity Management Team to Attend Opening Bell Ceremony on Thursday, October 7, 2021 at 9:30am E.T. REDWOOD CITY, CA / ACCESSWIRE / October 6, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced it will be ringing the Opening Bell on the Nasdaq Stock Market on Thursday, October 7, 2021 at 9:30am E.T.

Remote Medical Diagnostic Company, Biotricity, to Ring the Nasdaq Stock Market Opening Bell on Thursday, October 7th

Biokit is the Expansion of the Company's Bioflux Cardiac-Diagnostic Offering Kits on Track for Launch in Early 2022 REDWOOD CITY, CA / ACCESSWIRE / September 21, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that its Chief Executive Officer Dr. Waqaas Al-Siddiq is scheduled to present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 2:55 p.m. ET. Presentation Details: Date: Wednesday, September 22, 2021Time: 2:55 p.m.

Biotricity to Discuss Expansion of Remote Monitoring Medical Device Products at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd

Biotricity (NASDAQ: BTCY) is reforming the healthcare market as one of the fastest-growing companies in medtech. The company bridges the gap in remote cardiac monitoring, preventive and chronic care management by using the power of IoT (internet of things), wearables, and connected devices.

Biotricity Continues to Transform the Way We Do Health: Medtech Launches New Biokit Solution, Aims at Personal Health Monitoring

Company Expects New Personal Medical Device Kit to be available to customer by early 2022 REDWOOD CITY, CA / ACCESSWIRE / September 14, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has developed a personal medical device kit, Biokit, a bundled home-use set comprised of a digital thermometer, a pulse oximeter, and a blood pressure cuff. All three devices are FDA cleared, wireless capable and integrate into the Biotricity ecosystem, a platform for interconnectivity.

Biotricity Unveils "Biokit" with 3 Personal Medical Devices to Expand into Cardiac Disease Management

Underwritten Public Offering of Common Stock Resulted in Total Gross Proceeds of $16 Million REDWOOD CITY, CA / ACCESSWIRE / September 13, 2021 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that the underwriter of its previously announced underwritten public offering which closed on August 30, 2021, has partially exercised its option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commission. After giving effect to the sale of an aggregate of 382,331 additional shares pursuant to the exercise of the option, the total number of shares of common stock sold by the Company in the offering increased to 5,382,331 for total gross proceeds of approximately $16 million before deducting underwriting discounts and commissions and other offering expenses.

Biotricity Announces Closing of Exercise of Underwriter's Option to Purchase Additional Common Stock

Company's Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today reported its CEO Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m.

Biotricity to Discuss Sales Expansion, Recent Financing, and Wearable Medical Device Portfolio Expansion at H.C. Wainwright Conference

Biotricity (NASDAQ: BTCY) has been taking the world of medtech by storm, introducing primary care providers across the country to its remote heart monitoring devices. Always connected, these wearable devices have been giving power back to those suffering from chronic cardiac conditions and simultaneous comorbidities — the simultaneous presence of two or more diseases or medical conditions and often relative of one another.

Biotricity Reports Q1 Earnings at 290% for FY2022

Image via Biotricity.com Thursday, August 26, 2021, Biotricity, Inc. (NASDAQ: BTCY) uplisted to Nasdaq after raising $15 million to fuel its continued growth and expansion. Biotricity is a cardiac monitoring and data management company in the medtech arena that provides active, high-quality, real-time 24/7 monitoring and high-end clinical diagnostics through its Bioflux, flagship device.

News for Biotricity Stock (BTCY)